Inamed v. Medicis
This article was originally published in The Gray Sheet
Executive Summary
Restylane hyaluronic acid dermal filler marketer Medicis will challenge the validity of competitor Inamed's U.S. patent 4,803,075 in response to an infringement action brought by Inamed in San Diego federal court against Medicis and Restylane manufacturer Q-Med. The device was approved last December, four months ahead of Inamed's Hylaform (1"The Gray Sheet" April 26, 2004, In Brief). The patent covers use of a lubricant in dermal fillers to ease injection. Medicis notes that Inamed also is seeking a U.S. International Trade Commission investigation related to the alleged infringement. Medicis believes it has "meritorious defenses," maintaining that Q-Med cited the patent as prior art in its PMA application...